Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colin W Howden

Showing results (111-120 of 170) with videos related to

Pageof 17
Sort By:
Digestive Diseases and Sciences|February 22, 2002
Seroprevalence of H. pylori infection and symptoms of upper gastrointestinal tract disease in two groups of health-care workersTerence L Angtuaco, Virender K Sharma, Fred A Corder, et al.
American Journal of Therapeutics|September 23, 2008
Use of gastroprotection in patients discharged from hospital on nonsteroidal anti-inflammatory drugsGregory A Coté, John P Norvell, John P Rice, et al.
Digestion|April 16, 2011
Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortalityJames Y Lau, Joseph Sung, Catherine Hill, et al.
European Journal of Gastroenterology & Hepatology|April 23, 2020
Systematic review and meta-analysis: monopolar hemostatic forceps with soft coagulation in the treatment of peptic ulcer bleedingFaisal Kamal, Muhammad Ali Khan, Raseen Tariq, et al.
Alimentary Pharmacology & Therapeutics|April 21, 2023
Physiologically-based pharmacokinetic modelling to predict intragastric rifabutin concentrations in the treatment of Helicobacter pylori infectionColin W Howden, Shailja Shah, Salil N Pendse, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|November 18, 2024
Influence of patient characteristics on <i>Helicobacter pylori</i> eradication with Vonoprazan: A subgroup analysis of the pHalcon-HP trialWilliam D Chey, Francis Mégraud, Loren Laine, et al.
Journal of Clinical Pharmacology|December 22, 2021
A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race, Disease Status, and Other Covariates on ExposureCarmelo Scarpignato, Eckhard Leifke, Neila Smith, et al.
The American Journal of Gastroenterology|December 13, 2006
On-demand therapy for gastroesophageal reflux diseaseDavid C Metz, John M Inadomi, Colin W Howden, et al.
The American Journal of Gastroenterology|November 3, 2022
Response to GrahamLoren Laine, Prateek Sharma, Darcy J Mulford, et al.
The American Journal of Gastroenterology|March 16, 2022
Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US SubjectsLoren Laine, Prateek Sharma, Darcy J Mulford, et al.
Pageof 17

Showing results (111-120 of 170) with videos related to

Sort By:
Pageof 17
Digestive Diseases and Sciences|February 22, 2002
Seroprevalence of H. pylori infection and symptoms of upper gastrointestinal tract disease in two groups of health-care workersTerence L Angtuaco, Virender K Sharma, Fred A Corder, et al.
American Journal of Therapeutics|September 23, 2008
Use of gastroprotection in patients discharged from hospital on nonsteroidal anti-inflammatory drugsGregory A Coté, John P Norvell, John P Rice, et al.
Digestion|April 16, 2011
Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortalityJames Y Lau, Joseph Sung, Catherine Hill, et al.
European Journal of Gastroenterology & Hepatology|April 23, 2020
Systematic review and meta-analysis: monopolar hemostatic forceps with soft coagulation in the treatment of peptic ulcer bleedingFaisal Kamal, Muhammad Ali Khan, Raseen Tariq, et al.
Alimentary Pharmacology & Therapeutics|April 21, 2023
Physiologically-based pharmacokinetic modelling to predict intragastric rifabutin concentrations in the treatment of Helicobacter pylori infectionColin W Howden, Shailja Shah, Salil N Pendse, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|November 18, 2024
Influence of patient characteristics on <i>Helicobacter pylori</i> eradication with Vonoprazan: A subgroup analysis of the pHalcon-HP trialWilliam D Chey, Francis Mégraud, Loren Laine, et al.
Journal of Clinical Pharmacology|December 22, 2021
A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race, Disease Status, and Other Covariates on ExposureCarmelo Scarpignato, Eckhard Leifke, Neila Smith, et al.
The American Journal of Gastroenterology|December 13, 2006
On-demand therapy for gastroesophageal reflux diseaseDavid C Metz, John M Inadomi, Colin W Howden, et al.
The American Journal of Gastroenterology|November 3, 2022
Response to GrahamLoren Laine, Prateek Sharma, Darcy J Mulford, et al.
The American Journal of Gastroenterology|March 16, 2022
Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US SubjectsLoren Laine, Prateek Sharma, Darcy J Mulford, et al.
Pageof 17